TY - JOUR
T1 - Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO
T2 - an international Delphi study
AU - MASCC Mucositis Study Group
AU - Abdalla-Aslan, Ragda
AU - Bonomo, Pierluigi
AU - Keefe, Dorothy
AU - Blijlevens, Nicole
AU - Cao, Katrina
AU - Cheung, Yin Ting
AU - Fregnani, Eduardo Rodrigues
AU - Miller, Robert
AU - Raber-Durlacher, Judith
AU - Epstein, Joel
AU - Van Sebille, Ysabella
AU - Kauark-Fontes, Elisa
AU - Kandwal, Abhishek
AU - McCurdy-Franks, Emma
AU - Finkelstein, Joel
AU - McCarvell, Victoria
AU - Zadik, Yehuda
AU - Ottaviani, Giulia
AU - Amaral Mendes, Rui
AU - Speksnijder, Caroline Margina
AU - Wardill, Hannah Rose
AU - Bossi, Paolo
AU - Laheij, Alexa
AU - Tonkaboni, Arghavan
AU - Scott, Jacqui
AU - Abasaeed, Rania
AU - Kauzman, Adel
AU - Flato, Adriana Do Socorro Lima
AU - Gore, Adwaita
AU - Hardman, Anne Marie
AU - Horvath, Agnes
AU - Hovan, Allan
AU - Al-Jamaei, Aisha
AU - koizumi, Aya
AU - Santos-Silva, Alan
AU - Majorana, Alessandra
AU - Giannini, Alexandre
AU - Teixeira, Aléxia
AU - Shazib, Muhammad Ali
AU - Melvin, Alison
AU - Filho, Aluísio Miranda
AU - Gruza, Amanda
AU - Brown-Dahl, Amber
AU - Harilall, Amit
AU - El Maghrabi, Amr
AU - Rogulj, Ana Andabak
AU - Curvo, Ana Raphaela
AU - Soares, Ana Laura
AU - Stringer, Andrea
AU - Yarom, Noam
N1 - Publisher Copyright:
© 2024
PY - 2024/7
Y1 - 2024/7
N2 - Background: Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment. Methods: This study was conducted over two stages (January 2022–July 2023). The first phase involved a survey to MASCC-MSG members (January 2022–May 2022), capturing current practices, challenges and preferences. These then informed the second phase, in which a set of initial recommendations were prepared and refined using the Delphi method (February 2023–May 2023). Consensus was defined as agreement on a parameter by >80% of respondents. Findings: Seventy-two MASCC-MSG members completed the first phase of the study (37 females, 34 males, mainly oral care specialists). High variability was noted in the use of mucositis assessment tools, with a high reliance on clinician assessment compared to patient reported outcome measures (PROMs, 47% vs 3%, 37% used a combination). The World Health Organization (WHO) and Common Terminology Criteria for Adverse Events (CTCAE) scales were most commonly used to assess mucositis across multiple settings. Initial recommendations were reviewed by experienced MSG members and following two rounds of Delphi survey consensus was achieved in 91 of 100 recommendations. For example, in patients receiving chemotherapy, the recommended tool for clinician assessment in clinical practice is WHO for oral mucositis (89.5% consensus), and WHO or CTCAE for gastrointestinal mucositis (85.7% consensus). The recommended PROM in clinical trials is OMD/WQ for oral mucositis (93.3% consensus), and PRO-CTCAE for gastrointestinal mucositis (83.3% consensus). Interpretation: These new recommendations provide much needed guidance on mucositis assessment and may be applied in both clinical practice and research to streamline comparison and synthesis of global data sets, thus accelerating translation of new knowledge into clinical practice. Funding: No funding was received.
AB - Background: Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment. Methods: This study was conducted over two stages (January 2022–July 2023). The first phase involved a survey to MASCC-MSG members (January 2022–May 2022), capturing current practices, challenges and preferences. These then informed the second phase, in which a set of initial recommendations were prepared and refined using the Delphi method (February 2023–May 2023). Consensus was defined as agreement on a parameter by >80% of respondents. Findings: Seventy-two MASCC-MSG members completed the first phase of the study (37 females, 34 males, mainly oral care specialists). High variability was noted in the use of mucositis assessment tools, with a high reliance on clinician assessment compared to patient reported outcome measures (PROMs, 47% vs 3%, 37% used a combination). The World Health Organization (WHO) and Common Terminology Criteria for Adverse Events (CTCAE) scales were most commonly used to assess mucositis across multiple settings. Initial recommendations were reviewed by experienced MSG members and following two rounds of Delphi survey consensus was achieved in 91 of 100 recommendations. For example, in patients receiving chemotherapy, the recommended tool for clinician assessment in clinical practice is WHO for oral mucositis (89.5% consensus), and WHO or CTCAE for gastrointestinal mucositis (85.7% consensus). The recommended PROM in clinical trials is OMD/WQ for oral mucositis (93.3% consensus), and PRO-CTCAE for gastrointestinal mucositis (83.3% consensus). Interpretation: These new recommendations provide much needed guidance on mucositis assessment and may be applied in both clinical practice and research to streamline comparison and synthesis of global data sets, thus accelerating translation of new knowledge into clinical practice. Funding: No funding was received.
KW - Gastrointestinal mucositis
KW - Mucositis assessment tools
KW - Oral mucositis
KW - Patient-reported outcome measures
UR - http://www.scopus.com/inward/record.url?scp=85195281623&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2024.102675
DO - 10.1016/j.eclinm.2024.102675
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38933098
AN - SCOPUS:85195281623
SN - 2589-5370
VL - 73
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 102675
ER -